Latest news with #FactorVIII
Business Wire
26-06-2025
- Health
- Business Wire
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI™ (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The study met the primary endpoint and key secondary bleeding endpoints demonstrating the superiority of once-weekly subcutaneous HYMPAVZI in improving key bleeding outcomes compared to on-demand treatment in a patient population where less burdensome treatment approaches are needed. 1,2,3,4 Inhibitors, or antibodies, which neutralize factor replacement therapies and render them ineffective, may develop in people living with hemophilia. 5 Inhibitors can be diagnosed with a blood test. 6 Of the more than 800,000 people in the world living with hemophilia A or hemophilia B, approximately 20% of people with hemophilia A and 3% of people with hemophilia B are unable to continue taking factor replacement therapies because they develop inhibitors to FVIII (Factor VIII) and FIX (Factor IX) and these therapies no longer prevent or stop bleeding episodes. 6,7 'Patients with inhibitors tend to face frequent complications, and navigating the treatment landscape can introduce complexities and increase disease burden,' 1,2,3,4,8 said Davide Matino, M.D., BASIS Principal Investigator, Associate Professor of Medicine, McMaster University. 'The strong bleed reduction with HYMPAVZI compared to on-demand treatment in the Phase 3 BASIS study, coupled with its weekly administration method, offers exciting potential for these patients who are in critical need of treatment options.' The BASIS trial demonstrated that prophylactic treatment with HYMPAVZI resulted in a statistically significant and clinically relevant reduction in annualized bleeding rate (ABR) of treated bleeds in people living with severe hemophilia A or hemophilia B with inhibitors. Forty-eight people living with hemophilia were treated with HYMPAVZI during a 12-month period versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in the six-month lead-in period. HYMPAVZI was superior to on-demand treatment with a 93% reduction in ABR over 12 months (ABR 1.39 vs ABR on-demand 19.78; p < 0.0001). Superiority of HYMPAVZI was also demonstrated across all bleeding-related secondary endpoints—spontaneous bleeds, joint bleeds, target joint bleeds, and total bleeds. HYMPAVZI was generally well-tolerated, consistent with the non-inhibitor cohort of the BASIS study and Phase 1/2 results. No deaths or thromboembolic events were reported. 'These encouraging results demonstrate HYMPAVZI's potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,' said Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer. 'HYMPAVZI represents Pfizer's latest contribution in more than 40 years of working to advance hemophilia care, as a generally well-tolerated treatment option that could offer bleed protection with a straightforward, once-weekly subcutaneous administration in a pre-filled pen for patients with inhibitors, if approved in this patient population.' Analyses of the full Phase 3 dataset from the inhibitor cohort of the BASIS study are ongoing, and additional data will be presented at upcoming medical meetings. Pfizer plans to discuss these data with regulatory authorities, with the goal of initiating regulatory filings for HYMPAVZI for the treatment of patients living with hemophilia with inhibitors. Discovered by Pfizer scientists, HYMPAVZI has a mechanism of action that is differentiated from FVIII and FIX replacement treatments. Instead of replacing missing or insufficient clotting factors, HYMPAVZI is intentionally designed to target tissue factor pathway inhibitor (TFPI), one of the body's natural mechanisms that inhibits the initiation of blood clotting. By targeting the Kunitz 2 domain of TFPI, HYMPAVZI may help re-establish balance between bleeding and blood clot formation with the goal of offering a combination of bleed protection, good tolerability, and straightforward administration. About the BASIS study The pivotal BASIS study is a global Phase 3, open-label, multicenter study to evaluate the efficacy and safety of HYMPAVZI in adolescent and adult participants ages 12 to <75 years with severe hemophilia A (defined as FVIII <1%) or moderately severe to severe hemophilia B (defined as FIX activity ≤2%) with or without inhibitors. This cohort included 48 people living with hemophilia with inhibitors who were treated with HYMPAVZI during a 12-month active treatment period (ATP) versus an on-demand intravenous regimen with bypassing agents, administered as part of usual care in a six-month observational period. During the ATP, participants received prophylaxis (a 300 mg subcutaneous loading dose of HYMPAVZI, followed by 150 mg subcutaneously once weekly) with potential for dose escalation to 300 mg once weekly. An additional three patients in the inhibitor cohort were on routine prophylactic treatment prior to the study and not included in the primary efficacy analysis. The primary endpoint measures the treated ABR during the 12-month ATP with HYMPAVZI compared to treated ABR on prior on-demand replacement therapy. For further information, visit About HYMPAVZI HYMPAVZI has received regulatory approvals in the U.S. and in Europe for eligible patients living with hemophilia A without factor VIII inhibitors, or hemophilia B without factor IX inhibitors. HYMPAVZI was the first anti-TFPI approved in the U.S. and EU for the treatment of hemophilia A or B and the first hemophilia medicine approved in the U.S. and EU to be administered via a pre-filled, auto-injector pen. For eligible people living with hemophilia B, it is the first once-weekly subcutaneous prophylactic treatment. HYMPAVZI can offer a subcutaneous treatment option with a once-weekly dosing schedule and minimal preparation required for each individual administration. Pfizer is also conducting BASIS KIDS, an open-label study investigating the safety and efficacy of HYMPAVZI in children 1 to <18 years of age with severe hemophilia A or moderately severe to severe hemophilia B with or without inhibitors. About Hemophilia Hemophilia is a family of rare genetic blood diseases caused by a clotting factor deficiency (FVIII in hemophilia A, FIX in hemophilia B), which prevents normal blood clotting. Hemophilia is diagnosed in early childhood and impacts more than 800,000 people worldwide. 7 The inability of the blood to clot properly can increase the risk of painful bleeding inside the joints, which can cause joint scarring and damage. People living with hemophilia can suffer permanent joint damage following repeated bleeding episodes. 9,10 For decades, the most common treatment approach for hemophilia A and B has been factor replacement therapy, which replaces the missing clotting factors. Factor replacement therapies increase the amount of clotting factor in the body to levels that improve clotting, resulting in less bleeding. The burden of intravenous infusions is believed to be a barrier to treatment adherence for some people living with hemophilia due in part to inconvenience, time constraints, and poor venous access. 11 Approximately 20% of people with hemophilia A and 3% of people with hemophilia B are unable to continue taking factor replacement therapies because they develop inhibitors to FVIII and FIX. 6 These patients often have higher treatment burden, including potential complications from bleeding such as hospitalization and death, as well as higher treatment-related costs. 1,2,3,4,12 HYMPAVZI (marstacimab) U.S. Important Safety Information Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products (products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider's instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI. Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you: have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery. have a severe short-term (acute) illness such as an infection or injury. are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby. Females who are able to become pregnant: Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI. You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI. are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk. Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of HYMPAVZI? HYMPAVZI may cause serious side effects, including: blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot. Blood clots may form in blood vessels in your arm, leg, lung, or head and can be life-threatening. Get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in arms or legs redness or discoloration in your arms or legs shortness of breath pain in chest or upper back fast heart rate cough up blood feel faint headache numbness in your face eye pain or swelling trouble seeing allergic reactions. Allergic reactions, including rash and itching have happened in people treated with HYMPAVZI. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue trouble breathing wheezing dizziness or fainting fast heartbeat or pounding in your chest sweating The most common side effects of HYMPAVZI are injection site reactions, headache, and itching. These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. The full Prescribing Information can be found here. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at In addition, to learn more, please visit us on and follow us on X at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Disclosure notice The information contained in this release is as of June 26, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about HYMPAVZI™ (marstacimab), an anti-tissue factor pathway inhibitor, including its potential benefits and plans to discuss the Phase 3 BASIS data with regulatory authorities with the goal of initiating regulatory filings for HYMPAVZI for the treatment of patients living with hemophilia with inhibitors, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of HYMPAVZI; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed with regulatory authorities in particular jurisdictions for HYMPAVZI for any potential indication; whether and when any such applications that may be pending or filed for HYMPAVZI may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether HYMPAVZI will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of HYMPAVZI; risks and uncertainties related to issued or future executive orders or other new, or changes in, laws or regulations; uncertainties regarding the impact of COVID-19 on our business, operations and financial results; and competitive developments. A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned 'Risk Factors' and 'Forward-Looking Information and Factors That May Affect Future Results', as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at and 1 Shapiro AD, Ragni MV, Borhany M, et al. Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural). Haemophilia. 2021;27(1):49-59. doi: 10.1111/hae.14139. 2 Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004;10(2):134-46. doi: 10.1046/j.1365-2516.2003.00840.x. 3 Nugent D, Kalnins W, Querol F, et al. Haemophilia Experiences, Results and Opportunities (HERO) study: Treatment-related characteristics of the population. Haemophilia. 2015;21(1):e26-38. doi: 10.1111/hae.12545. 4 Soucie JM, Symons Jt, Evatt B, Brettler D, Huszti H, Linden J. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia. 2001;7(2):198-206. doi: 10.1046/j.1365-2516.2001.00484.x. 5 Teiu P, Chan A, Matino D. Molecular Mechanisms of Inhibitor Development in Hemophilia. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020001. doi: 10.4084/MJHID.2020.001. 6 Centers of Disease Control and Prevention. Testing for Inhibitors and Hemophilia. Accessed May 14, 2025. Available at: 7 World Federation of Hemophilia. World Federation of Hemophilia Global Report on the Annual Global Survey 2022. 8 Meeks S, Batsuli G. Hemophilia and inhibitors: Current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):657–662. doi: 10.1182/asheducation-2016.1.657. 9 Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd Edition; 2020. Haemophilia. 26(S6), 1–158. 10 Franchini M, Mannucci PM. Past, present and future of hemophilia: A narrative review. Orphanet J Rare Dis. 2012;7:24. 11 Weyand AC, Pipe SW. New therapies for hemophilia. Blood. 2019;133(5):389–398. 12 Walsh CE, Soucie JM, Miller CH. Impact of inhibitors on hemophilia a mortality in the United States. Am. J. Hematol. 2015; 90: 400-405. Category: Medicines
Hindustan Times
20-06-2025
- Health
- Hindustan Times
After months of delay, Maharashtra approves ₹45 crore for haemophilia drugs
Mumbai: After months of disruption caused by the Centre halting the supply of life-saving anti-haemophilic factors (AHFs), the Maharashtra government has sanctioned ₹45 crore for the urgent procurement of clotting factor injections used in the treatment of haemophilia. This includes Factor VII and Factor VIII (both plasma-derived and recombinant forms), Factor IX, and FEIBA (Anti-Inhibitor Coagulant Complex). These essential drugs are critical for preventing fatal bleeds in patients with haemophilia, a rare genetic blood-clotting disorder. An AHF is a protein naturally produced in the human body that plays a crucial role in blood clotting. The state's approval, formalised in a government resolution dated June 18, covers the purchase of over 100,000 vials of AHFs. This includes 25,147 vials of Factor VIII, 21,835 vials of Recombinant Factor VIII, 18,520 vials of Factor IX, and 4,605 vials of FEIBA. These medications fall under the government's essential drug list and will be distributed across Maharashtra through designated day-care haemophilia centres. The intervention comes in response to a policy shift by the Union health ministry, which earlier redirected funding from tertiary medical colleges to district hospitals. Previously, centrally allocated funds were used by institutions like Mumbai's KEM Hospital to procure AHFs. However, under the revised guidelines, civic-run institutions such as KEM no longer qualify for central support. This has crippled services at KEM, despite the hospital treating over 950 haemophilia patients from across Maharashtra. In one instance, a 29-year-old IT professional from Mira Road, suffering from severe joint and muscle bleeding, was turned away by the Thane Civil Hospital and referred to KEM. Due to critical shortages, he received only two units of Factor VIII—far below the therapeutic dose based on body weight—sharply increasing the risk of long-term disability. In cases of internal or brain bleeding, such delays could be fatal. Crucial policy shift Dr Mahendra Kendre, assistant director (blood cell) at the Directorate of Health Services, said the state's decision marks a crucial policy shift to safeguard haemophilia care. 'The withdrawal of central funding from medical colleges like KEM disrupted access to life-saving treatment,' he said. 'With this dedicated state budget and procurement policy, we are ensuring patients are no longer left vulnerable and that treatment continuity is maintained across Maharashtra.' As per the new directive, AHFs must now be stocked at all haemophilia daycare centres across the state. These drugs are significantly more expensive than standard medicines—some costing up to ₹40,000 per vial—and are essential to prevent life-threatening bleeds and irreversible joint damage. While the state's intervention brings relief, systemic flaws still threaten treatment continuity. 'Companies bid without maintaining stock, and the system allows it. Patients are paying the price,' said Jigar Kotecha, secretary of the Mumbai chapter of the Haemophilia Society, an NGO. Frequent tender failures and delivery delays have left patients vulnerable. The new budget and streamlined procurement policy aim to fix these gaps, ensuring steady access to life-saving drugs and preventing further avoidable harm. The Haemophilia Society is demanding a more robust procurement framework, timely stock replenishment, and the inclusion of advanced therapies such as extended half-life factors and non-factor treatments for patients who develop inhibitors. In a letter to the health ministry, the NGO also urged the government not to deny AHF supplies to hospitals like KEM until a capable alternative is formally designated. 'We are not asking for luxuries; we are asking for survival,' Kotecha wrote. With no dedicated civil hospital in Mumbai and tertiary centres excluded from federal schemes, advocacy groups have urged Maharashtra to adopt successful models from states like Gujarat and Telangana. Until then, patients remain reliant on emergency fixes and fragile supply chains.
Scottish Sun
27-05-2025
- Health
- Scottish Sun
I had no idea I had hep C for 40 years – my GP failed to tell me I tested positive as it slowly destroyed my life
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) FRANK Jamieson says his GP practice failed to tell him he had a potentially deadly virus - more than 20 years after he tested positive. 'It has ruined my life", the 58-year-old, from Inverclyde, in Scotland, said. Sign up for Scottish Sun newsletter Sign up 1 Frank believes hepatitis C might have affected his ability to have children Credit: SWNS "I have suffered from depression for a long time and have lost everything". Frank was only told last October that he had hepatitis C, which he likely contracted 40 years ago during a leg operation after a road accident in 1984. Hep C is a blood-borne virus which, left untreated, can cause liver cancer and liver failure. It usually displays no symptoms until the virus damages the liver enough to cause liver disease, at which point it can cause fatigue and difficulty concentrating. 'My health was so bad, and I had no idea why," Frank said. "It turned out they were all symptoms of hep C,' he added. It is also linked to cardiovascular disease, mental health issues, kidney disease and musculoskeletal pain. Frank's infection is part of the wider contaminated blood scandal, which saw thousands in Scotland and the UK infected with hepatitis C and HIV from NHS blood products in the 1970s and 80s. He later discovered his GP surgery, Ardgowan Medical Practice in Greenock, knew he tested positive back in 2002, with results confirmed in January 2003. 'The surgery had my results but they never passed them on,' Frank said. Infected Blood Inquiry: Police should look into prosecutions says Labour MP 'After all those years of going to the doctor, and that information being on my file, they are blaming me.' Frank's positive test came just as he and his now wife were preparing for another round of IVF. 'I had my blood tests taken in late 2002 because my now wife and I were set to go through another round of IVF,' he said. 'We had two unsuccessful tries on the NHS and were going to pay for a third.' But that Christmas, both lost their jobs when the company closed, halting their plans. 'Our lives fell apart. We still got married, but we couldn't afford the IVF, so we weren't able to try again,' Frank explained. What is the infected blood scandal? More than 30,000 people in the UK were infected with HIV and hepatitis C after being given contaminated blood products in the 1970s and 1980s. As many as 140,000 bereaved parents, children and siblings of victims may also be able to claim compensation in their own right Two main groups of NHS patients were affected by what has been called the biggest treatment disaster in the history of the NHS. Firstly, haemophiliacs - and those with similar disorders - who have a rare genetic condition which means their blood does not clot properly. People with haemophilia A have a shortage of a clotting agent called Factor VIII, while people with haemophilia B do not have enough Factor IX. In the 1970s, a new treatment using donated human blood plasma was developed to replace these clotting agents. But entire batches were contaminated with deadly viruses. After being given the infected treatments, about 1,250 people in the UK with bleeding disorders went on to develop both HIV and hepatitis C, including 380 children. About two-thirds later died of Aids-related illnesses. Some unintentionally gave HIV to their partners. Another 2,400 to 5,000 people developed hepatitis C on its own, which can cause cirrhosis and liver cancer. It is difficult to know the exact number of people infected with hepatitis C, partly because it can take decades for symptoms to appear. A second group of patients were given contaminated blood transfusions after childbirth, surgery or other medical treatment between 1970 and 1991. The inquiry estimates that between 80 and 100 of these people were infected with HIV, and about 27,000 with hepatitis C. In total, it is thought about 2,900 people have died. He added: 'Hepatitis C can cause infertility. We would have known that then if we'd had the results.' The practice told Frank patients had to call within seven days for test results - but they have no record of him ever making that call. 'I asked them, where were the results all those years? Were they sitting in a drawer until I phoned?' he added. The virus caused Frank severe health problems, including nerve and joint pain and Raynaud's phenomenon - symptoms that appeared five years ago. 'I have been suicidal' Fortunately, Frank, who worked as an engineer until ill health forced him to give up work, is now free of hep C after undergoing anti-viral treatment. He is now under the care of the SAMH charity (Scottish Action for Mental Health) as well as the NHS's local community mental health team. They are helping him manage his depression and ongoing health challenges. 'I have been suicidal,' he said. 'Right now, I don't want to be here.' Frank hopes to raise awareness so others in Inverclyde don't suffer the same fate. 'There might be other people out there who have missed blood test results, who have hep C or something else and who don't know,' he warned. Now free of the virus after antiviral treatment, Frank is determined to hold his GP practice accountable. 'I want justice. I want to be heard, and I want Ardgowan Medical Practice to take responsibility for what happened,' he said. His complaints to the Scottish Public Services Ombudsman were rejected due to the passage of time. But Frank is pursuing support through the Scottish Infected Blood Support Scheme - a body that helps people infected by NHS blood products with compensation and support. 'My journey is just beginning,' he said. Ardgowan Medical Practice declined to comment when approached by the Greenock Telegraph. The Sun has also contacted the Practice, who again, declined to comment.
North Wales Chronicle
20-05-2025
- Health
- North Wales Chronicle
The British Blood Scandal: Poisoned at School
The British Blood Scandal: Poisoned at School focuses on the stories of haemophiliac children at the Lord Mayor Treloar School in Hampshire. They were sent to the specialist boarding school with the promise of a 'normal childhood', but instead became victims of secret medical research which left many of them with Hepatitis and HIV. A summary on the Radio Times website adds: "Revealing the true stories of the students of The Lord Mayor Treloar School and Hospital, a place where young haemophiliacs were given Factor VIII, a drug they thought was a cure but was actually a death sentence. "Through deeply personal testimony, this documentary pieces together a story of secret clinical trials, medical negligence and the fight for truth at the heart of the worst medical disaster in NHS history." Of the 122 haemophiliacs who attended Treloar's in the 1970s and 1980s, only around 30 are still alive today. Jo Clinton-Davis, Controller of Factual ITV, said: 'As they continue their fight for justice, the raw truth of how thousands were affected by the 1970s and 1980s infected blood scandal is told by some of the last remaining victims themselves in this emotional documentary. "It's shocking how these men have suffered all these years from something that was covered up and could have been prevented.' Our next film 'The British Blood Scandal: Poisoned at School' is coming to ITV and ITVX at 9pm on the 20th of May! Read about it on our website here - Anna Hall, Executive Producer at Candour Productions, said: 'The British Blood Scandal: Poisoned at School shows the devastating effect first-hand of a lifetime spent unearthing what happened to our survivors when they were just children. "We are so humbled to have worked with the four men in this film who wanted to make this in honour of their school friends who died, so that the truth would finally be told.' As reported by BBC News, in the 1970s and 1980s, more than 30,000 people in the UK were infected with HIV and hepatitis C after being given contaminated blood products. One group that was impacted by this were haemophiliacs, who had rare disorders which meant their blood didn't clot properly. Set your reminders, Tuesday 20th May ITV 9pm (Also available to stream on ITV X) The British Blood Scandal: Poisoned at School 💔💛🖤@chriswardmp @metpoliceuk @sussex_police @HaemoSocUK @UN @EHC_Haemophilia @wfhemophilia @ukhomeoffice @YvetteCooperMP @MoJGovUK @wesstreeting In the 1970s, a new treatment using donated human blood plasma was developed to replace clotting agents in haemophiliacs, but entire batches were contaminated with deadly viruses. An inquiry found that about 1,250 people in the UK with bleeding disorders went on to develop both HIV and hepatitis C, including 380 children. About two-thirds later died of Aids-related illnesses, with some unintentionally passing it onto their partners. Recommended reading: ITV to release documentary about infected blood scandal featuring victims' stories Which blood type is the rarest? How to find out your blood type The best exercise to lower your blood pressure according to new study Another 2,400 to 5,000 people developed hepatitis C on its own, which can cause cirrhosis and liver cancer. BBC News adds: "It is difficult to know the exact number of people infected with hepatitis C, partly because it can take decades for symptoms to appear." A second group of patients were given contaminated blood transfusions after childbirth, surgery or other medical treatment between 1970 and 1991. In total, it is thought around 3,000 people have died due to the infected blood scandal.
Yahoo
20-05-2025
- Entertainment
- Yahoo
How to watch new ITV documentary on British contaminated blood scandal
A new ITV documentary relating to the British contaminated blood scandal will be airing tonight (Tuesday, May 20). The British Blood Scandal: Poisoned at School focuses on the stories of haemophiliac children at the Lord Mayor Treloar School in Hampshire. They were sent to the specialist boarding school with the promise of a 'normal childhood', but instead became victims of secret medical research which left many of them with Hepatitis and HIV. A summary on the Radio Times website adds: "Revealing the true stories of the students of The Lord Mayor Treloar School and Hospital, a place where young haemophiliacs were given Factor VIII, a drug they thought was a cure but was actually a death sentence. "Through deeply personal testimony, this documentary pieces together a story of secret clinical trials, medical negligence and the fight for truth at the heart of the worst medical disaster in NHS history." Of the 122 haemophiliacs who attended Treloar's in the 1970s and 1980s, only around 30 are still alive today. Jo Clinton-Davis, Controller of Factual ITV, said: 'As they continue their fight for justice, the raw truth of how thousands were affected by the 1970s and 1980s infected blood scandal is told by some of the last remaining victims themselves in this emotional documentary. "It's shocking how these men have suffered all these years from something that was covered up and could have been prevented.' Our next film 'The British Blood Scandal: Poisoned at School' is coming to ITV and ITVX at 9pm on the 20th of May! Read about it on our website here - — Candour Productions (@CandourTV) May 16, 2025 Anna Hall, Executive Producer at Candour Productions, said: 'The British Blood Scandal: Poisoned at School shows the devastating effect first-hand of a lifetime spent unearthing what happened to our survivors when they were just children. "We are so humbled to have worked with the four men in this film who wanted to make this in honour of their school friends who died, so that the truth would finally be told.' As reported by BBC News, in the 1970s and 1980s, more than 30,000 people in the UK were infected with HIV and hepatitis C after being given contaminated blood products. One group that was impacted by this were haemophiliacs, who had rare disorders which meant their blood didn't clot properly. Set your reminders, Tuesday 20th May ITV 9pm (Also available to stream on ITV X) The British Blood Scandal: Poisoned at School 💔💛🖤@chriswardmp @metpoliceuk @sussex_police @HaemoSocUK @UN @EHC_Haemophilia @wfhemophilia @ukhomeoffice @YvetteCooperMP @MoJGovUK @wesstreeting — Mark Antony Ward (@Haemosexual) May 14, 2025 In the 1970s, a new treatment using donated human blood plasma was developed to replace clotting agents in haemophiliacs, but entire batches were contaminated with deadly viruses. An inquiry found that about 1,250 people in the UK with bleeding disorders went on to develop both HIV and hepatitis C, including 380 children. About two-thirds later died of Aids-related illnesses, with some unintentionally passing it onto their partners. Recommended reading: ITV to release documentary about infected blood scandal featuring victims' stories Which blood type is the rarest? How to find out your blood type The best exercise to lower your blood pressure according to new study Another 2,400 to 5,000 people developed hepatitis C on its own, which can cause cirrhosis and liver cancer. BBC News adds: "It is difficult to know the exact number of people infected with hepatitis C, partly because it can take decades for symptoms to appear." A second group of patients were given contaminated blood transfusions after childbirth, surgery or other medical treatment between 1970 and 1991. In total, it is thought around 3,000 people have died due to the infected blood scandal.
